Men’s Health – Time to Change Our Approach
A recent analysis in the UK suggested that men have a nearly three-fold higher rate of death from bladder cancer and twice as high a rate of death from kidney cancer than women.1,2
Testosterone – A Point of Focus for Men’s Health?
For all cancers
except non-melanoma skin cancer, breast cancer and the sex-specific cancers, men had a 69% higher rate of death and a 62% higher incidence rate when considering all age groups.1,2
When viewing the total cancer burden, men still seem to have a disadvantage. Considering deaths in the UK in 2007, cancer accounted for 29% of total mortality for men compared with 25% in women; when translated into age-standardised rates, the contrast is more profound, with death rates of 211.3 males and 153.1 females per 100,000 cancer cases.3
The mean age of death for the same group
of cancers is approximately three years earlier for men in the UK. An additional 37,000 years of life are presumably lost as a result of the higher rate of premature death.4
Cancer survival also has a gender component. Micheli et al.5 found
that women in each age class had significantly higher survival than men for all cancers combined; however, this advantage reduced progressively with age. It is possible to surmise that the cause of this increased risk of developing and dying from non-sex-specific cancers is a combination of multiple factors. These include lifestyle, e.g. smoking, alcohol, diet, central obesity, germ line (impact of inherited and acquired genetic mutations), female biological advantage and health behaviour factors, e.g. delay in presenting with symptoms.2,4
There is an absence of men from preventative health services and a lack of recognition of the need to reach out to men to ensure that cancers are either prevented or at least picked up and treated aggressively at the first opportunity. Recognition and consideration of this situation should be the absolute minimum requirement to try and reduce the burden of cancer in men.
Prostate Health – A New Gateway to Men’s Health
Prostate cancer is the most common non-cutaneous cancer in men and the second most common cause of cancer death. Most men who reach average life expectancy will experience benign prostatic hyperplasia or prostate cancer at some stage in their life. These conditions account for a considerable amount of ill-health and distress for men and their, often neglected, partners. The goal for any cancer should be to understand an individual patient’s risk of developing the disease and to detect the cancer while it is still localised and treatable. The International Society of Men’s Health (ISMH) believes that raising awareness of prostate health and prostate disease will empower and motivate men to consult their physician. It will also be a promoter and catalyst for detecting many other existing or underlying conditions and co-morbidities. The most important goals are to empower men to manage their own health and to talk about worries regarding their health.
1. National Cancer Intelligence Network, Cancer Research UK, Centre for Men’s Health at Leeds Metropolitan University, Men’s Heath Forum, The Excess Burden of Cancer in Men in the UK, 2009, Cancer Research UK, 2009. Available at:
http://info.cancerresearchuk.org/prod_consump/ groups/cr_common/@nre/@sta/documents/generalconten t/crukmig_1000ast-2748.pdf
2.
Shariat SF, Sfakianos JP, Droller MJ, et al., The effect of age and gender on bladder cancer: a critical review of the literature, BJU Int, 2010;105(3):300–08.
Hypogonadism due to all causes may affect up to 30% of men. It can have negative effects on health and quality of life, including decreased lean body mass and increased fat mass, decreased bone mineral density, fatigue, decreased libido and sexual function and negative mood states. Unfortunately, hypogonadism remains underdiagnosed and undertreated, with only about 5% of men with the condition being treated for it. The concern of some physicians about the potential for testosterone replacement treatment to stimulate prostate cancer is not supported by decades of data accumulated to date, although studies of longer duration (e.g. 10 years or more) would be even more convincing.
Several recent studies have shown that testosterone insufficiency in older men is associated with increased risk of death over the next 20 years independent of multiple risk factors and several pre-existing health conditions.6
In men, endogenous testosterone concentrations are inversely related to mortality due to cardiovascular disease and all causes. Low testosterone may be a predictive marker for those at high risk of cardiovascular disease.7
The Future of Men’s Health
A range of actions are needed to improve men’s health. However, it is important that these are taken within the context of achieving greater health equality between the sexes. This should help to ensure that there are also parallel improvements in women’s health and that the sexes are not pitted against each other in a competition for resources.
Health policy and practice needs to take greater account of the differences between men in relation to social class, ethnicity, age, sexual orientation and disability in order to tackle men’s health problems effectively. It is for this reason that, starting with the Men’s Health World Congress 2010 (
www.ismh.org/worldcongress), the ISMH proposes an initiative to join forces to ‘bridge the gap’. It aims to initiate a joint effort uniting international scientific societies as well as medical organisations in the field of men’s health, urology, andrology, cardiovascular health, diabetes, obesity and primary care. The congress will receive contributions from various national experts.
The main objectives are to increase awareness of the neglected field of men’s health, especially its multi- and interdisciplinary nature, and to propose policy recommendations for a more holistic approach to male healthcare and support.
The ISMH hopes that many more researchers and contributors from all fields of medicine will take up the challenge and conduct good collaborative interdisciplinary studies to answer key men’s health issues that are vital to elevating men’s health status throughout the world. n
3. US Department of Health and Human Services, National Center for Health Statistics Health, United States, 2008 With Chartbook, Hyattsville, MD, 2009.
4. 5.
White A, Thomson CS, Forman D, et al., Men’s health and the excess burden of cancer in men, European Urol, 2010;9( Suppl. 3):467–70.
Micheli A, Ciampichinia R, Oberaignerb W, et al., The advantage of women in cancer survival: an a nalysis of EUROCARE-4 data, Eur J Cancer, 2009;45:
1017–27.
6. Laughlin GA, Barrett-Connor E, Bergstrom J, Low serum testosterone and mortality in older men, J Clin Endocrinol Metab, 2008;93:68-75.
7.
Khaw KT, Dowsett M, Folkerd E, et al., Endogenous testosterone and mortality due to all causes, crdiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective popuation study, Circulation, 2007;116:2694–2701.
EUROPEAN UROLOGICAL REVIEW 11
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84